Cargando…

Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study

BACKGROUND: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). METHODS: The data of patients with locally advanced resectable ESCC (staging cT2N + M0,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenzhong, Yi, Yang, Jia, Yinghui, Dong, Xiaoxin, Zhang, Junxia, Song, Xiaomeng, Song, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930492/
https://www.ncbi.nlm.nih.gov/pubmed/35118824
http://dx.doi.org/10.1111/1759-7714.14328
_version_ 1784671072323371008
author Wang, Wenzhong
Yi, Yang
Jia, Yinghui
Dong, Xiaoxin
Zhang, Junxia
Song, Xiaomeng
Song, Yan
author_facet Wang, Wenzhong
Yi, Yang
Jia, Yinghui
Dong, Xiaoxin
Zhang, Junxia
Song, Xiaomeng
Song, Yan
author_sort Wang, Wenzhong
collection PubMed
description BACKGROUND: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). METHODS: The data of patients with locally advanced resectable ESCC (staging cT2N + M0, cT3‐4aNanyM0, IA‐IVA) who received preoperative chemotherapy with liposomal paclitaxel plus platinum (cisplatin, nedaplatin or carboplatin) in HuanXing Cancer Hospital from July 2018 to October 2019 were collected. The primary endpoint of this study was R0 resection rate, and secondary endpoints were pathological complete response (pCR) rate, 1‐ and 2‐year overall survival (OS) rate, 1‐year and 18‐month disease‐free survival (DFS) rate, and safety. RESULTS: A total of 32 eligible patients were included in this study. All patients received neoadjuvant chemotherapy and surgery. The R0 resection rate was 93.8%, the pCR rate was 12.5%, and down‐staging was achieved in 14 patients (47.8%). Median follow‐up was 31.0 months (95% confidence interval [CI] 30.1–31.9 months). The 1‐ and 2‐year OS rates were 96.9% and 78.1%, and the 1‐year and 18‐month DFS rates were 86.7% and 76.7%, respectively. The median DFS and OS were not reached. The incidence rate of neoadjuvant chemotherapy related grade 3–4 adverse events was 21.9%, including neutropenia (21.9%) and leukopenia (9.4%). CONCLUSIONS: The results of this study suggest that liposomal paclitaxel combined with platinum as neoadjuvant chemotherapy can provide satisfactory R0 resection rate and survival rate, and significant tumor down‐staging effect for patients with locally advanced resectable ESCC, with safety profile.
format Online
Article
Text
id pubmed-8930492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-89304922022-03-24 Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study Wang, Wenzhong Yi, Yang Jia, Yinghui Dong, Xiaoxin Zhang, Junxia Song, Xiaomeng Song, Yan Thorac Cancer Original Articles BACKGROUND: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). METHODS: The data of patients with locally advanced resectable ESCC (staging cT2N + M0, cT3‐4aNanyM0, IA‐IVA) who received preoperative chemotherapy with liposomal paclitaxel plus platinum (cisplatin, nedaplatin or carboplatin) in HuanXing Cancer Hospital from July 2018 to October 2019 were collected. The primary endpoint of this study was R0 resection rate, and secondary endpoints were pathological complete response (pCR) rate, 1‐ and 2‐year overall survival (OS) rate, 1‐year and 18‐month disease‐free survival (DFS) rate, and safety. RESULTS: A total of 32 eligible patients were included in this study. All patients received neoadjuvant chemotherapy and surgery. The R0 resection rate was 93.8%, the pCR rate was 12.5%, and down‐staging was achieved in 14 patients (47.8%). Median follow‐up was 31.0 months (95% confidence interval [CI] 30.1–31.9 months). The 1‐ and 2‐year OS rates were 96.9% and 78.1%, and the 1‐year and 18‐month DFS rates were 86.7% and 76.7%, respectively. The median DFS and OS were not reached. The incidence rate of neoadjuvant chemotherapy related grade 3–4 adverse events was 21.9%, including neutropenia (21.9%) and leukopenia (9.4%). CONCLUSIONS: The results of this study suggest that liposomal paclitaxel combined with platinum as neoadjuvant chemotherapy can provide satisfactory R0 resection rate and survival rate, and significant tumor down‐staging effect for patients with locally advanced resectable ESCC, with safety profile. John Wiley & Sons Australia, Ltd 2022-02-04 2022-03 /pmc/articles/PMC8930492/ /pubmed/35118824 http://dx.doi.org/10.1111/1759-7714.14328 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Wang, Wenzhong
Yi, Yang
Jia, Yinghui
Dong, Xiaoxin
Zhang, Junxia
Song, Xiaomeng
Song, Yan
Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
title Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
title_full Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
title_fullStr Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
title_full_unstemmed Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
title_short Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study
title_sort neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: results from a retrospective study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930492/
https://www.ncbi.nlm.nih.gov/pubmed/35118824
http://dx.doi.org/10.1111/1759-7714.14328
work_keys_str_mv AT wangwenzhong neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy
AT yiyang neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy
AT jiayinghui neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy
AT dongxiaoxin neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy
AT zhangjunxia neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy
AT songxiaomeng neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy
AT songyan neoadjuvantchemotherapywithliposomalpaclitaxelplusplatinumforlocallyadvancedesophagealsquamouscellcancerresultsfromaretrospectivestudy